Optimizing the diabetic formulary: Beyond aspirin and insulin

Journal of the American College of Cardiology

Volumn 40, Issue 4, 2002, Pages 652-661

  Marso, Steven P ^a  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM ANTAGONIST; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; FOSINOPRIL; GEMFIBROZIL; INSULIN; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; VALSARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ETHNOLOGY; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; FORMULARIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MORTALITY; PLATELET AGGREGATION INHIBITORS; UNITED STATES;

EID: 0037151607     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02006-5     Document Type: Review

References (84)

1. Prevalence of the metabolic syndrome among U.S. adults: Findings from the third National Health and Nutrition Examination Survey
2. Heart disease and diabetes
3. Diabetes in America: Epidemiology and scope of the problem
4. U.S. public health and the 21st century: Diabetes mellitus
5. Diabetes and decline in heart disease mortality in U.S. adults
6. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
7. Report of the expert committee on the diagnosis and classification of diabetes mellitus
8. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
9. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: The Rancho Bernardo Study
10. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: The Hoorn Study
11. Hyperglycemia and cardiovascular disease in type 2 diabetes
12. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk)
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group
14. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state
15. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents
16. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study
17. Banting lecture: Insulin action, diaberogenes, and the cause of type II diabetes
18. Insulin and risk of cardiovascular disease: A meta-analysis
19. Elevated C-reactive protein levels in overweight and obese adults
20. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
21. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaβ
22. Reduction of insulin resistance in obese and/or diabetic animals by 5- [4-(1-methyl-cyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent
23. Characterization of CS-045, a new oral antidiabetic agent, II: Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice
24. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice
25. Studies on hindered phenols and analogues, 1: Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation
26. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
27. Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation
28. You are what you secrete
29. The hormone resistin links obesity to diabetes
30. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
31. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
32. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study
33. Pathophysiology and pharmacological treatment of insulin resistance
34. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human subcutaneous adipocytes
35. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia
36. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
37. Effects of troglitazone on lipoprotein sub-classes in patients who are insulin resistant
38. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
39. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
40. Activators of the nuclear receptor PPARgamma enhance colon polyp formation
41. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension
42. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals
43. Cardiovascular risk factors and cognitive decline in middle-aged adults
44. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly
45. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease
46. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
47. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
48. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
49. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
50. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: Data from the GISSI-3 study
51. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
52. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
53. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
54. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
55. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM
56. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
57. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
58. ACE inhibitor-versus angiotensin II blocker-induced cough and angioedema
59. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
60. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
61. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
62. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: Retrospective data from two large studies
63. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
64. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease
65. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: A randomized, controlled trial
66. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience
67. Compensatory enlargement of human atherosclerotic coronary arteries
68. Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients
69. Diabetes as an atherogenic factor
70. Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease
71. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo
72. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus
73. Potential mechanisms promoting restenosis in diabetic patients
74. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients
75. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
76. Physician's Health Study: Aspirin and primary prevention of coronary heart disease
77. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14
78. Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus
79. Diabetes mellitus is associated with an increased risk of in-hospital death following elective percutaneous coronary intervention: An analysis of 18,309 patients
80. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy
81. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
82. Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?